50 related articles for article (PubMed ID: 20362634)
1. Susceptibility in vitro of Epstein-Barr Virus to myristoylated-peptide.
Ourth DD
Peptides; 2010 Jul; 31(7):1409-11. PubMed ID: 20362634
[TBL] [Abstract][Full Text] [Related]
2. (Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents.
Qiu YL; Ptak RG; Breitenbach JM; Lin JS; Cheng YC; Kern ER; Drach JC; Zemlicka J
Antivir Chem Chemother; 1998 Jul; 9(4):341-52. PubMed ID: 9875413
[TBL] [Abstract][Full Text] [Related]
3. Antitumor cell activity in vitro by myristoylated-peptide.
Ourth DD
Biomed Pharmacother; 2011 Jul; 65(4):271-4. PubMed ID: 21741202
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity against human immunodeficiency virus-1 in vitro by myristoylated-peptide from Heliothis virescens.
Ourth DD
Biochem Biophys Res Commun; 2004 Jul; 320(1):190-6. PubMed ID: 15207720
[TBL] [Abstract][Full Text] [Related]
5. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
6. Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma.
Jenson HB; Montalvo EA; McClain KL; Ench Y; Heard P; Christy BA; Dewalt-Hagan PJ; Moyer MP
J Med Virol; 1999 Jan; 57(1):36-46. PubMed ID: 9890420
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus (EBV) replication and expressions of EA-D (BMRF1 gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-activated Akata cells.
Daibata M; Sairenji T
Virology; 1993 Oct; 196(2):900-4. PubMed ID: 8396819
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents.
Lin JS; Kira T; Gullen E; Choi Y; Qu F; Chu CK; Cheng YC
J Med Chem; 1999 Jun; 42(12):2212-7. PubMed ID: 10377226
[TBL] [Abstract][Full Text] [Related]
9. Screening of drugs inhibiting Epstein-Barr virus replication.
Liu MY; Yen HK; Chern JW; Tsai CH; Yang CS; Chen JY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1996 May; 29(2):80-9. PubMed ID: 10592789
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Epstein-Barr virus reproduction--ribonucleosides of 3-substituted 1,2,4-triazino[5,6-b] [1,4] benzothiasines.
Golovan AJ; Nesterova NV; Zagorodnya SD; Alexeeva LV; Palchykovska LI; Usenko LS; Baranova GV
Mikrobiol Z; 2010; 72(2):36-42. PubMed ID: 20455440
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus infections: prospects for treatment.
Gershburg E; Pagano JS
J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression.
Ballout M; Germi R; Fafi-Kremer S; Guimet J; Barguès G; Seigneurin JM; Morand P
J Virol Methods; 2007 Jul; 143(1):38-44. PubMed ID: 17368820
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
16. Contrasting effects of hydroxyurea on cell growth and reduction in Epstein-Barr virus genomes in EBV-infected epithelioid cell lines vs Burkitt's lymphoma cell lines.
Jiang R; Kanamori M; Satoh Y; Fukuda M; Ikuta K; Murakami M; Sairenji T
J Med Virol; 2003 Jun; 70(2):244-52. PubMed ID: 12696111
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
18. Potential in vitro activity of Kutapressin against Epstein-Barr virus.
Rosenfeld E; Salimi B; O'Gorman MR; Lawyer C; Katz BZ
In Vivo; 1996; 10(3):313-8. PubMed ID: 8797033
[TBL] [Abstract][Full Text] [Related]
19. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis.
Peng M; Lundgren E
Oncogene; 1992 Sep; 7(9):1775-82. PubMed ID: 1354347
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets.
De Leo A; Arena G; Lacanna E; Oliviero G; Colavita F; Mattia E
Antiviral Res; 2012 Nov; 96(2):196-202. PubMed ID: 22985630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
